BeOne Medicines Ltd.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: BeOne Medicines Ltd.
Former names: BeiGene, Ltd.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Headquarters city: Basel
Headquarters country: Cayman Islands
Fiscal year end: December
Ticker symbol: ONC
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001651308
EIN: 98-1209416

Board of directors

Follow this board

Alessandro Riva · Director
Since 2023
Anthony C. Hooper · Director
Since 2023
Charles Lazelle Sawyers · Director
Since 2026
Corazon (Corsee) D. Sanders · Director
Since 2023
Donald W. Glazer · Director
Since 2023
Elizabeth Fisher Mooney · Director
Since 2026
Felix Baker · Director Overboarded
Since 2023
John Oyler · Director · Chief Executive Officer
Since 2023
Julian Baker · Director Overboarded
Since 2023
Margaret Dugan · Director
Since 2023
Olivier Brandicourt · Director
Since 2024
Qingqing Yi · Director
Since 2023
Shalini Sharp · Director Overboarded
Since 2024
Thomas Malley · Director
Since 2023
Xiaodong Wang · Director
Since 2023

Chief executives

John Oyler · Chief Executive Officer

Dates unknown

Director election results

Annual meeting of June 11, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

8 of this board's directors also sit on 27 other boards. 27 are in the same sector.

Shared director Other board Same sector +11 more in the list below

Bicycle Therapeutics plc Same sector
via Alessandro Riva, Felix Baker and Julian Baker
Kiniksa Pharmaceuticals International plc Same sector
via Felix Baker, Julian Baker and Thomas Malley
ACADIA Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
DBV Technologies S.A. Same sector
via Felix Baker and Julian Baker
Denali Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Immunocore Holdings plc Same sector
via Felix Baker and Julian Baker
Incyte Corp. Same sector
via Felix Baker and Julian Baker
Kodiak Sciences Inc Same sector
via Felix Baker and Julian Baker
Kymera Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Madrigal Pharmaceuticals Inc. Same sector
via Felix Baker and Julian Baker
Neurogene Inc. Same sector
via Felix Baker and Julian Baker
Prelude Therapeutics Incorporated Same sector
via Felix Baker and Julian Baker
Replimune Group Inc. Same sector
via Felix Baker and Julian Baker
TScan Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
vTv Therapeutics Inc. Same sector
via Felix Baker and Julian Baker
Alnylam Pharmaceuticals Inc. Same sector
via Olivier Brandicourt
Calidi Biotherapeutics Inc. Same sector
via Corazon (Corsee) D. Sanders
Century Therapeutics Inc. Same sector
via Alessandro Riva
Iambic Therapeutics Inc. Same sector
via Shalini Sharp
Kura Oncology Inc. Same sector
via Thomas Malley
Legend Biotech Corporation Same sector
via Corazon (Corsee) D. Sanders
MannKind Corporation Same sector
via Anthony C. Hooper
Neurocrine Biosciences Inc. Same sector
via Shalini Sharp
Organon & Co. Same sector
via Shalini Sharp
Septerna Inc. Same sector
via Shalini Sharp
Ultragenyx Pharmaceutical Inc. Same sector
via Corazon (Corsee) D. Sanders
Vaxcyte Inc. Same sector
via Olivier Brandicourt

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $381,536,826; 214 sales by 12 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 6, 2026	Ball Titus B. Officer (Principal Accounting Officer)	Option exercise	+880	$207.55	$182,644
Nov 6, 2026	Ball Titus B. Officer (Principal Accounting Officer)	Option exercise	+679	$159.03	$107,981
Nov 6, 2026	Ball Titus B. Officer (Principal Accounting Officer)	Open-market sale	−1,533	$405.55	$621,712
Nov 6, 2026	Ball Titus B. Officer (Principal Accounting Officer)	Open-market sale	−26	$406.34	$10,565
Nov 5, 2026	Lee Chan Henry Officer (SVP, General Counsel)	Open-market sale	−660	$400.00	$264,000
Nov 5, 2026	Lee Chan Henry Officer (SVP, General Counsel)	Open-market sale	−455	$402.00	$182,910
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Option exercise	+31,028	$36.90	$1,144,933
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−880	$355.56	$312,892
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−1,440	$355.62	$512,087
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−1,239	$357.54	$442,990
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−1,681	$358.75	$603,052
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−1,280	$359.72	$460,444
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−320	$360.64	$115,404
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−2,331	$362.35	$844,639
Oct 27, 2026	Xiaodong Wang Director, Chair, Scientific Advisory Brd	Open-market sale	−8,148	$363.24	$2,959,696

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

Adlai Nortye Group Ltd. Nasdaq: ANL · Singapore, Cayman Islands Organization Herbalife Ltd. NYSE: HLF · George Town, Cayman Islands Organization 3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization

Questions about BeOne Medicines Ltd.

Who is the CEO of BeOne Medicines Ltd.?

John Oyler is BeOne Medicines Ltd.'s Chief Executive Officer.

How many directors are on BeOne Medicines Ltd.'s board?

BeOne Medicines Ltd.'s board has 15 directors: Alessandro Riva, Anthony C. Hooper, Charles Lazelle Sawyers, Corazon (Corsee) D. Sanders, Donald W. Glazer, Elizabeth Fisher Mooney, Felix Baker, John Oyler, Julian Baker, Margaret Dugan and 5 others.

Are BeOne Medicines Ltd. insiders buying or selling shares?

Over the last 12 months, BeOne Medicines Ltd. insiders made no open-market purchases and sold $381.5 million of shares in 214 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is BeOne Medicines Ltd. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="beone-medicines-ltd"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.